Dr. James Mackay, Ph.D. - CEO, Crystalys Therapeutics - Next Generation Treatments For Gout

Dr. James Mackay, Ph.D. is President, Chief Executive Officer and co-founder of Crystalys Therapeutics Inc. ( https://crystalystx.com/ ), a development stage pharmaceutical company addressing the significant unmet medical needs of people living with gout and dedicated to developing new therapeutics and helping improve the lives of patients.

Dr. Mackay has over 40 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. Prior to founding Crystalys Therapeutics, he was CEO and co-founder of Aristea Therapeutics and President and CEO of Ardea Biosciences.  

Prior to Ardea, Dr. Mackay held senior executive positions over a 30 year period at AstraZeneca where he led the development and commercialization of drugs across a range of therapy areas and managed significant global functional departments.

Dr. Mackay plays a pivotal role in the San Diego innovation ecosystem and currently sits on the Board and Executive Committee of CONNECT and sits on the Board of Advisors of BIOCOM. He is a former Board member of the San Diego Economic Development Corporation (EDC). 

Dr. Mackay holds a BS in Genetics and Ph.D. in Medical Genetics from Aberdeen University, Scotland.

Important Episode Link - 

JEWEL Program - https://jewelprogram.com/

#JamesMackay #CrystalysTherapeutics #Gout #CrystalInducedArthritis #UricAcid #Hyperuricemia #GoutyArthritis #Allopurinol #UrateLoweringTherapy #XanthineOxidaseInhibitors #UricosuricAgents #Dotinurad #TophaceousGout #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast